Drugs / Sacubitril/Valsartan
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03832660 Comparator | May 2019 → May 2022 | hypertrophic cardiomyopathy | Newcastle University | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sacubitril/Valsartan | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03832660 ↗ |
| Action | Inhibit | “angiotensin receptor neprilysin inhibitor” NCT03832660 ↗ |
| Route | Oral | “each taken by mouth twice daily” NCT03832660 ↗ |